Selected CAR T-cell combination trials
| Clinicaltrials.gov registration no. . | Trial . | Lymphoma subtypes . | Regimen . |
|---|---|---|---|
| NCT02926833 | ZUMA-6 | DLBCL | axi-cel+atezolizumab |
| NCT03630159 | PORTIA | DLBCL | tisa-cel+pembrolizumab |
| NCT03310619 | PLATFORM | DLBCL, FL 3B, EBV+DLBCL, PMBL, HGBCL, T-cell histocyte-rich large B-cell lymphoma | liso-cel+durvalumab; liso-cel+CC-122; liso-cel+CC-220; liso-cel+ibrutinib |
| NCT03876028 | — | DLBCL | tisa-cel+ibrutinib |
| Clinicaltrials.gov registration no. . | Trial . | Lymphoma subtypes . | Regimen . |
|---|---|---|---|
| NCT02926833 | ZUMA-6 | DLBCL | axi-cel+atezolizumab |
| NCT03630159 | PORTIA | DLBCL | tisa-cel+pembrolizumab |
| NCT03310619 | PLATFORM | DLBCL, FL 3B, EBV+DLBCL, PMBL, HGBCL, T-cell histocyte-rich large B-cell lymphoma | liso-cel+durvalumab; liso-cel+CC-122; liso-cel+CC-220; liso-cel+ibrutinib |
| NCT03876028 | — | DLBCL | tisa-cel+ibrutinib |